GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rockwell Medical Inc (NAS:RMTI) » Definitions » EBITDA per Share

Rockwell Medical (Rockwell Medical) EBITDA per Share : $-0.24 (TTM As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Rockwell Medical EBITDA per Share?

Rockwell Medical's EBITDA per Share for the three months ended in Dec. 2023 was $0.01. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.24.

During the past 3 years, the average EBITDA per Share Growth Rate was 62.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 47.20% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 21.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Rockwell Medical's EBITDA per Share or its related term are showing as below:

RMTI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -165   Med: 17.15   Max: 62.7
Current: 62.7

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Rockwell Medical was 62.70% per year. The lowest was -165.00% per year. And the median was 17.15% per year.

RMTI's 3-Year EBITDA Growth Rate is ranked better than
93.82% of 858 companies
in the Drug Manufacturers industry
Industry Median: 8.4 vs RMTI: 62.70

Rockwell Medical's EBITDA for the three months ended in Dec. 2023 was $0.15 Mil.

During the past 3 years, the average EBITDA Growth Rate was 44.00% per year. During the past 5 years, the average EBITDA Growth Rate was 27.70% per year. During the past 10 years, the average EBITDA Growth Rate was 7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Rockwell Medical was 44.00% per year. The lowest was -229.50% per year. And the median was 5.25% per year.


Rockwell Medical EBITDA per Share Historical Data

The historical data trend for Rockwell Medical's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rockwell Medical EBITDA per Share Chart

Rockwell Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.68 -3.89 -3.26 -1.13 -0.20

Rockwell Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.07 -0.15 -0.03 0.01

Rockwell Medical EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Rockwell Medical's EBITDA per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA per Share(A: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-4.694/23.323
=-0.20

Rockwell Medical's EBITDA per Share for the quarter that ended in Dec. 2023 is calculated as

EBITDA per Share(Q: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=0.146/28.711
=0.01

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rockwell Medical  (NAS:RMTI) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Rockwell Medical EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Rockwell Medical's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Rockwell Medical (Rockwell Medical) Business Description

Traded in Other Exchanges
Address
30142 S. Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. Rockwell Medical's mission is to provide dialysis clinics and patients with the highest quality products supported by the best customer service in the industry. It is focused on innovative, long-term growth strategies that enhance products, processes, and people, enabling the company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients.
Executives
Jesse Neri officer: SVP, FINANCE 851 DUPORTAIL ROAD, SECOND FLOOR, CHESTERBROOK PA 19087
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Russell Skibsted officer: See Remarks 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Megan C. Timmins officer: SVP, General Counsel 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Mark Strobeck director, officer: President and CEO 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Allen Nissenson director 601 HAWAII ST., EL SEGUNDO CA 90245
Robert S Radie director 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
David S. Richmond 10 percent owner, other: See Footnote 1 3568 WILDWOOD AVENUE, JACKSON MI 49202
Russell H Ellison director 270 RIVERSIDE DR., APT. 12D, NEW YORK NY 10025
Marc L Hoffman officer: Chief Medical Officer 30142 WIXOM ROAD, WIXOM MI 48393
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Richmond Brothers, Inc. 10 percent owner, other: See Footnote 1 7415 FOXWORTH COURT, JACKSON MI 49201
Stuart M Paul director, officer: Chief Executive Officer HOME DIAGNOSTICS, INC., 2400 NW 55TH COURT, FORT LAUDERDALE FL 33309
Angus W. Smith officer: Chief Financial Officer C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960